Skip to main content

Advertisement

SpringerLink
Log in

Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease

  • Clinical Article
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Background

123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is a useful tool for differentiating idiopathic Parkinson's disease (PD) from other parkinsonian syndromes, but its prognostic value in PD has not been established. The objective of this study was to clarify the correlation between cardiac MIBG uptake parameters and the outcome in PD patients subjected to the subthalamic nucleus stimulation.

Method

We enrolled 31 consecutive PD patients and calculated the heart-to-mediastinum ratio (H/M) and washout rate (WR) based on the activity measured at 15 min (early phase) and 3 h (delayed phase) after the intravenous injection of MIBG (111 MBq). Cardinal motor symptoms and activity of daily living (ADL) were assessed on the Unified Parkinson's Disease Rating Scale (UPDRS) and Schwab and England (S–E) ADL scale, before and 3 months after surgery.

Findings

Neither early nor delayed H/M correlated with any of the preoperative subscores on the UPDRS or S–E, nor with postoperative outcome. On the other hand, increased WR was a positive predictor for postoperative improvement rate on S–E in medication-off state (p = 0.00003). Also, WR showed a more faint but significant correlation with preoperative levodopa responsiveness on S–E (p = 0.008).

Conclusion

Our findings suggest that 123I-MIBG scintigraphy in combination with levodopa-responsiveness evaluation may represent a useful tool for prediction of outcomes in patients subjected to STN stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, Ando M (1994) Radiolabelled metaiodobenzylguanidine in assessment of autonomic dysfunction. Lancet 343:984–985

    Article  CAS  PubMed  Google Scholar 

  2. Braak H, Tredici KD, Rüb U, de Vos RAI, Ernst NH, Steur ENHJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211

    Article  PubMed  Google Scholar 

  3. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, Pollak P (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59:932–934

    CAS  PubMed  Google Scholar 

  4. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH (2009) MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism- predominant multiple system atrophy. Mov Disord 24:1650–1655

    Article  PubMed  Google Scholar 

  5. Erola T, Heikkinen ER, Haapaniemi T, Tuominen J, Juolasmaa A, Myllylä VV (2006) Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease. Acta Neurochir (Wien) 148:389–394

    Article  CAS  Google Scholar 

  6. Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, Hirayama M, Takahashi A (1994) A radiological analysis of heart sympathetic functions with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84

    Article  CAS  PubMed  Google Scholar 

  7. Hallett M, Litvan I (1999) The task force on surgery for Parkinson's disease. Evaluation of surgery for Parkinson's disease. A report of the therapeutic and technology assessment subcommittee of the American academy of neurology. Neurology 53:1910–1921

    CAS  PubMed  Google Scholar 

  8. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body disease. Neurology 52:1269–1271

    CAS  PubMed  Google Scholar 

  9. Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2008) Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 49:907–914

    Article  PubMed  Google Scholar 

  10. Katayama Y, Kasai M, Oshima H, Fukaya C, Yamamato T, Ogawa K, Mizutani T (2001) Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. J Neurosurg 95:213–221

    Article  CAS  PubMed  Google Scholar 

  11. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21(Suppl 14):S290–S304

    Article  PubMed  Google Scholar 

  12. Krack P, Batir A, van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin P, Benazzouz A, LeBas JF, Benabid A-L, Pollak P (2003) A five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Eng J Med 349:1925–1934

    Article  CAS  Google Scholar 

  13. Langston JW (2006) The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59:591–596

    Article  PubMed  Google Scholar 

  14. Lyons KE, Davis JT, Pahwa R (2007) Subthalamic stimulation in Parkinson's disease patients intolerant to levodopa. Stereotact Funct Neurosurg 85:169–174

    Article  PubMed  Google Scholar 

  15. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P (1992) Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A.　Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477

    CAS  PubMed  Google Scholar 

  16. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53:85–90

    CAS  PubMed  Google Scholar 

  17. Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, Nakazato M, Yamashita S, Arita H, Nishii R, Kawai K (2008) Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 22:557–564

    Article  PubMed  Google Scholar 

  18. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76:249–251

    Article  CAS  PubMed  Google Scholar 

  19. Orimo S, Ozawa E, Oka T, Nakade S, Tsuchiya K, Yoshimoto M, Wakabayashi K, Takahashi H (2001) Differentional histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57:1140–1141

    CAS  PubMed  Google Scholar 

  20. Østergaard K, Sunde N, Dupont E (2002) Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 17:693–700

    Article  PubMed  Google Scholar 

  21. Post KK, Singer C, Papapetropoulos S (2008) Cardiac denervation and dysautonomia in Parkinson's disease: a review of screening techniques. Parkinsonism Relat Disord 14:524–531

    Article  PubMed  Google Scholar 

  22. Romito LM, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A (2002) Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology 58:1546–1550

    CAS  PubMed  Google Scholar 

  23. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K (2000) Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573

    Article  CAS  PubMed  Google Scholar 

  24. Taki J, Yoshita M, Yamada M, Tonami N (2004) Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 18:453–461

    Article  PubMed  Google Scholar 

  25. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL (2008) Prognostic value of myocardinal 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systemic review. Eur Heart J 29:1147–1159

    Article  PubMed  Google Scholar 

  26. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 58:396–401

    PubMed  Google Scholar 

  27. Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Agid Y et al (2002) Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 125:575–583

    Article  CAS  PubMed  Google Scholar 

  28. Yamada K, Goto S, Hamasaki T, Kuratsu J-I (2008) Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Acta Neurochir (Wien) 150:15–22

    Article  CAS  Google Scholar 

  29. Yamada K, Goto S, Kuratsu J, Matsuzaki K, Nagahiro S, Shimazu H, Kaji R (2007) General anesthesia for stereotactic implantation of stimulating electrodes within the subthalamic nucleus. Parkinsonism Relat Disord 13:101–107

    Article  PubMed  Google Scholar 

  30. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, Yamada M (2006) 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850–1854

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a foundation subscribed by Hokuto Hospital, Obihiro, Hokkaido, Japan.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Kazumichi Yamada & Jun-ichi Kuratsu

  2. Department of Diagnostic Imaging, Graduate School of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan

    Shin-ya Shiraishi

  3. Department of Neurosurgery, National Hospital Organization Kagoshima Medical Center, Kagoshima, 892-0853, Japan

    Tadashi Hamasaki

Authors
  1. Kazumichi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin-ya Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadashi Hamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun-ichi Kuratsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazumichi Yamada.

Additional information

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a foundation subscribed by Hokuto Hospital, Obihiro, Hokkaido, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamada, K., Shiraishi, Sy., Hamasaki, T. et al. Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease. Acta Neurochir 152, 2063–2068 (2010). https://doi.org/10.1007/s00701-010-0825-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-010-0825-0

Keywords

Search

Navigation